Source comparison
PT-141 vs Viagra Mechanism Effectiveness Compared: Clinical Comparison
Before interpreting this table: effectiveness is context-dependent. PT-141's 'effectiveness' is measured by changes in subjective desire scores and frequency of satisfying sexual events. Metrics that don't apply to Viagra trials, which measure erectile rigidit
This comparison does not assign a generated winner or score.
- Before interpreting this table: effectiveness is context-dependent. PT-141's 'effectiveness' is measured by changes in subjective desire scores and frequency of satisfying sexual events. Metrics that don't apply to Viagra trials, which measure erectile rigidity and ability to achieve penetration. Comparing these directly is methodologically flawed, but the table clarifies where each compound succeeds within its intended use case.
- Primary Mechanism
- Melanocortin-4 receptor agonist in hypothalamus. Stimulates CNS arousal pathways
- PDE5 inhibitor in penile smooth muscle. Sustains cGMP-mediated vasodilation
- Entirely different biological targets with zero overlap
- Site of Action
- Central nervous system (paraventricular nucleus)
- Peripheral vascular tissue (corpus cavernosum)
- PT-141 is a brain drug; Viagra is a vascular drug
- Onset Time
- 45–90 minutes subcutaneous injection
- 30–60 minutes oral administration
- Viagra acts faster but requires existing arousal stimulus
- Duration of Effect
- 6–12 hours
- 4–6 hours
- PT-141 has longer active window but lower peak intensity
- Primary Approved Use
- Hypoactive sexual desire disorder in premenopausal women (FDA 2019)
- Erectile dysfunction in men (FDA 1998)
- Non-overlapping patient populations
- Efficacy in Women
- Statistically significant increase in satisfying sexual events vs placebo (RECONNECT trial)
- Minimal to no benefit. Female sexual dysfunction is rarely PDE5-mediated
- PT-141 addresses desire; Viagra addresses mechanical flow
- Efficacy in Men (Erectile Dysfunction)
- Off-label use with limited clinical data. May improve desire but not rigidity
- 60–80% improvement in erectile function scores in vascular-origin ED
- Viagra is first-line standard of care; PT-141 is not
- Most Common Adverse Event
- Nausea (40%), transient hypertension
- Headache (16%), flushing, visual disturbances
- Side effect profiles reflect different receptor targets